Mr Casey William Sasser, FNP-BC | |
3443 Dickerson Pike Ste 680, Nashville, TN 37207-2537 | |
(615) 865-3322 | |
(615) 467-6692 |
Full Name | Mr Casey William Sasser |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 3443 Dickerson Pike Ste 680, Nashville, Tennessee |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275774051 | NPI | - | NPPES |
1516161 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 14020 (Tennessee) | Secondary |
363LF0000X | Nurse Practitioner - Family | APN0000014020 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Casey William Sasser, FNP-BC 719 Thompson Ln Ste 30330, Nashville, TN 37204-4701 Ph: () - | Mr Casey William Sasser, FNP-BC 3443 Dickerson Pike Ste 680, Nashville, TN 37207-2537 Ph: (615) 865-3322 |
News Archive
CeltiCare today announced that the Commonwealth has accepted its proposal to manage healthcare services for Aliens with Special Status (AWSS). This population has been enrolled in the Commonwealth Care insurance program (Commonwealth Care) run by the Massachusetts Health Connector.
The identification of oncogenic mutations has provided further insights into the tumorigenesis of meningioma and the possibility of targeted therapy.
Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.
BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.
› Verified 7 days ago